 |
MAHESH V. PATEL (President and CEO) has more than fifteen years of technology and product development experience in the area of drug discovery
support, drug delivery and product line extensions. Prior to co-founding Lipocine in 1997, Patel led drug delivery research and development at Pharmacia and
Upjohn, Kalamazoo, MI. He received his M.S. in physical pharmacy at the University of Cincinnati and his Ph.D. in pharmaceutics from the University of Utah.
His areas of expertise include strategic planning, technology assessment/development, technical management, and product research and development. |
 |
SRINIVASAN VENKATESHWARAN (Chief Technology Officer, Vice President of Research and Development) has more than 15 years of experience in
leading the development of innovative drug delivery-based technologies and products at several drug delivery companies. Held positions as Executive Director
of R&D at Mylan Technologies Inc., and Executive Director, Transdermal and Inhalation Research at TheraTech Inc. /Watson Labs, Utah, where he spearheaded
technology and product development. Venkateshwaran received his Ph.D. and M. S. in Chemical Engineering from the University of Utah and a B. Tech in Chemical
Engineering from the Indian Institute of Technology, Mumbai. |
 |
GERALD T. SIMMONS (Corporate Business Development Officer) brings 20 + years of large pharmaceutical and early stage drug development company
experience. Mr. Simmons has held corporate business positions at Pharmacraft (now Ciba- Geigy) and Vice President, New Venture Group at Schering Plough Corp.
After Schering Plough, Mr. Simmons held CEO assignments for Cellegy Pharmaceuticals, a drug delivery company, MantiCore Pharmaceuticals, an oncology company,
and Fountain Pharmaceuticals, a drug delivery company. He managed Cellegy from a seed financing stage through an IPO (NASDAQ-CLGY), and is a Director of
MantiCore. Mr. Simmons received is MBA from the University of Buffalo and BA from Canisius College. |
 |
Robert K. Merrell (Vice President of Finance) has more than 15 years of financial and general management experience in the pharmaceutical
industry. Most recently, he was a Vice President at Myriad Genetics Laboratories. Prior to Myriad, Mr. Merrell was CFO at NPS Pharmaceuticals where he
provided financial leadership in enabling NPSs growth from an early stage company through successful IPO and three subsequent follow-on offerings raising
approximately $300 million. He was also actively involved in mergers and acquisitions. Prior to NPS, he was a senior manager at KPMG Peat Marwick. He is a CPA and
earned his graduate degree in management at Kellogg Graduate School of Management and his bachelor degree in accounting at The University of Utah. |
|
Management
